Nan-Jing Peng

Dr. Nan-Jing Peng


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HCHong-Tai Chang
Hong-Tai Chang
CHChin Hu
Chin Hu
YCYu-Li Chiu
Yu-Li Chiu
NPNan-Jing Peng
Nan-Jing Peng
RLRen-Shyan Liu
Ren-Shyan Liu
To evaluate the usefulness of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of breast cancer tumor recurrences and its role in post-therapy surveillance. FDG-PET/CT was performed on patients with increased serum CA 15-3 levels and/or clinical/radiologic suspicion of recurrence. A group of asymptomatic patients who underwent FDG-PET/CT in the post-therapy surveillance of breast cancer served as the controls. The results were analyzed based on the patients' histological data, other imaging modalities and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 12 months of the FDG-PET/CT scan. Based on elevated serum CA15-3 levels (n = 31) and clinical/radiologic suspicion (n = 40), 71 scans were performed due to suspected recurrence, whereas 69 scans were performed for asymptomatic follow-up. The sensitivity and specificity of FDG-PET/CT were 87.5% and 87.1% in the patients with suspected recurrence and 77.8% and 91.7% in the asymptomatic patients. The positive predictive value in the patients with suspected recurrence (mainly due to elevated serum CA 15-3 levels) was higher than that in asymptomatic patients (P = 0.013). Recurrences were proven in 56.3% (40/71) of the patients with suspected recurrence and in 13% (9/69) of the asymptomatic patients (P<0.001). FDG-PET/CT resulted in changes in the planned management in 49.3% (35/71) of the patients with suspected recurrence and 10.1% (7/69) of the asymptomatic patients (P<0.001). After follow-up, 77.5% (55/71) of the patients with suspicious recurrences and 97.1% (67/69) of the asymptomatic patients were surviving at the end of the study (P<0.001). FDG-PET/CT was able to detect recurrence, and the results altered the intended patient management in the post-therapy surveillance of breast cancer. FDG-PET/CT should be used as a priority in patients with increased serum CA 15-3 levels, or with clinical/radiologic suspicion of recurrence, and might be useful for asymptomatic patients.

1 April 2011 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
NPNan-Jing Peng
Nan-Jing Peng
WLWen-Shiung Liou
Wen-Shiung Liou
RLRen-Shyan Liu
Ren-Shyan Liu
CHChin Hu
Chin Hu
DTDaw-Guey Tsay
Daw-Guey Tsay
CLCheng-Bin Liu
Cheng-Bin Liu
Serum CA-125 has been shown to be a sensitive tumor marker of recurrent ovarian cancer. The goal of this study was to evaluate the use of 2-[F-18]fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels. Patients who demonstrated a normalization of serum CA-125 levels after complete remission of ovarian cancer were recruited for this study. FDG-PET/CT was performed to evaluate serum CA-125 levels ≥ 35 U/mL (Group 1) or progressive low-level increases in the levels of serum CA-125 (Group 2). The results were analyzed based on pathology, disease progression, and/or clinical follow-up. Twenty-seven (27) consecutive patients consented to the aforementioned criteria (n = 16 in Group 1 and n = 11 in Group 2). In Group 1, of the 16 patients, 15 had a proven tumor recurrence, and the remaining 1 had a second primary cancer with no evidence of recurrent ovarian lesions. In Group 2, all 11 patients had recurrent tumors. The use of FDG-PET/CT allowed the detection of recurrences in 25 patients and a second primary cancer in 1 patient, which included all of the patients in Group 1 and 10 of the 11 patients in Group 2. The detection rate of FDG-PET/CT for recurrent ovarian cancer was 100% in Group 1 and 90.9% in Group 2 (15/15 vs. 10/11, p = 0.423). FDG-PET/CT changed the intended management in 14 (53.8%) of the patients, which included 4 cases in Group 1 and 10 cases in Group 2. FDG-PET/CT has the ability to detect recurrent ovarian cancer and second primary tumors in patients with increased levels of serum CA-125. FDG-PET/CT affects the clinical management by localizing recurrent lesions and creating a specific treatment plan for each patient, especially patients who demonstrate a low-level increase in serum CA-125 levels.

10 December 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYu-Chang Hu
Yu-Chang Hu
KTKuo-Wang Tsai
Kuo-Wang Tsai
Ching-Chi LeeChing-Chi Lee
Ching-Chi Lee
NPNan-Jing Peng
Nan-Jing Peng
CJChien Ju-chun
Chien Ju-chun
WLWen-Shan Liu
Wen-Shan Liu
Adaptive radiotherapy (ART) has potential benefits in patients with nasopharyngeal cancer (NPC). This retrospective study aimed to identify the factors favoring ART. Forty NPC patients were retrospectively included in this study. All patients received two-phase, volumetric modulated arc radiotherapy (VMAT) and underwent a second computed tomography (CT) for the phase II ART. We generated phantom, non-ART plans by a hybrid method for comparison with ART plans. A paired t-test was used to evaluate the dose differences between these two plans. A subgroup analysis through a paired t-test was used to evaluate the factors favoring ART. The second CT images were captured at the median 22 fractions. The median total dose of the planning target volume-one (PTV-1) was 72 Gy, and the phase II dose was 16 Gy. The volumes of the ipsilateral parotid gland (23.2 vs. 19.2 ml, p < 0.000), contralateral parotid gland (23.0 vs. 18.4 ml, p < 0.000), clinical target volume-1 (CTV-1, 32.2 vs. 20.9 ml, p < 0.000), and PTV-1 (125.8 vs. 107.3 ml, p < 0.000) all shrunk significantly between these two CT simulation procedures. Among the nearby critical organs, only the ipsilateral parotid gland displayed significant dose reduction by the ART plan (5.3 vs. 6.0 Gy, p = 0.004). Compared to the phantom plan, the ART could significantly improve the PTV-1 target volume coverage of D98 (15.4 vs. 12.3 Gy, p < 0.000). Based on the D98 of PTV-1, the factors of a large initial weight (> 60 kg, p < 0.000), large body mass index (BMI) (> 21.5, p < 0.000), obvious weight loss (> 2.8 kg, p < 0.000), concurrent chemoradiotherapy (p < 0.000), and stages III–IV (p < 0.000) favored the use of ART. ART could significantly reduce the mean dose to the ipsilateral parotid gland. ART has dosimetrical benefit for patients with a heavy initial weight, large BMI, obvious weight loss, concurrent chemoradiotherapy, and cancer in stages III–IV.

27 December 2019 in In Vivo
Verified
Journal Article
Closed access
PDF file
HCHung-Pin Chan
Hung-Pin Chan
WLWen-Shan Liu
Wen-Shan Liu
WLWen-Shiung Liou
Wen-Shiung Liou
CHChin Hu
Chin Hu
YCYu-Li Chiu
Yu-Li Chiu
NPNan-Jing Peng
Nan-Jing Peng
Background/Aim: Whole-body positron-emission tomography/computed tomography with the glucose analog 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been used to screen examinees for underlying malignancy in many countries. The aim of this study was to compare the potential value of FDG-PET/CT application in asymptomatic individuals with those with suspected malignancy. Patients and Methods: A total of 9,408 examinees underwent whole-body FDG-PET/CT at our hospital from July 2006 to August 2013. Three thousand and seven hundred asymptomatic individuals and 848 individuals with laboratory and clinical/radiologicaI suspicion of malignancy who had undergone FDG-PET/CT for cancer screening were recruited. The final confirmation of cancer and outcomes were based on a pathological report and continuous follow-up. Results: Forty-five out of 3,700 asymptomatic individuals (1.2%) had proven malignancy, and 42 of them (93.3%) were found by FDG-PET/CT. Two hundred and twelve out of 848 with suspected malignancy (25%) had proven malignancy, and 196 of them (92.5%) were detected by FDG-PET/CT. Most of these cancers in asymptomatic individuals were clinically at an early stage. The discovery rate in asymptomatic individuals and those with suspected malignancy was 1.1% and 23.1%, respectively. The overall survival of patients with cancer diagnosed with PET/CT was higher than those with suspected malignancy (78.6% vs. 48.5%, p<0.001). Patients with a resectable lesion, early-stage disease, and lower maximal standardized uptake value had significantly better survival than those without. Conclusion: FDG-PET/CT is useful in the early diagnosis of cancer and thus might improve the survival rates of these patients. Considering the costs and risk of radiation exposure, it would be better used as a priority in patients with laboratory and clinical/radiologic suspicion of malignancy.

1 July 2013 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
NPNan-Jing Peng
Nan-Jing Peng
CHChin Hu
Chin Hu
TKTai-Ming King
Tai-Ming King
YCYu-Li Chiu
Yu-Li Chiu
JWJui-Ho Wang
Jui-Ho Wang
RLRen-Shyan Liu
Ren-Shyan Liu
To evaluate the usefulness of 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of resectable recurrences of colorectal cancer (CRC) and the impacts on the clinical disease management. FDG-PET/CT was performed on patients with elevated serum carcinoembryonic antigen (CEA) levels >5 ng/mL (Group 1) or suspicious recurrences without rise in serum CEA levels (Group 2). The results were analyzed on the basis of histological data, disease progression, and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of the FDG-PET/CT scan. Resectable recurrences and changes in management were calculated based on medical records. In our study, 128 consecutive FDG-PET/CT analyses (n=49 in Group 1 and n=79 in Group 2) were performed on 96 recruited patients. Recurrences were proven in 63. The overall sensitivity, specificity, and accuracy of FDG-PET/CT were 98.4%, 89.2%, and 93.8%, respectively, and were 100%, 88.9%, and 95.9% in Group 1 and 96.9% and 89.4% and 92.4% in Group 2, respectively. Surgical resections were performed in 38.7% (12/31) of Group 1 patients and 53.1% (17/32) of Group 2 patients. FDG-PET/CT induced changes in planned management in 48.4% (62/128) of all patients, which included 63.3% (31/49) of Group 1 patients and 39.2% (31/79) of Group 2 patients (p=0.008). After a follow-up, 3.4% (1/29) of patients who underwent surgical resection of recurrent lesions and 34.3% (11/34) patients who did not undergo resection died at the end of study (p=0.004). The surgical resection of limited recurrent disease, as determined by FDG-PET/CT, improves the survival of CRC patients. FDG-PET/CT should be performed not only in patients with elevated serum CEA levels, but also in those in whom recurrences are suspected to improve the early detection of resectable disease.

1 November 2016 in Medicine
Verified
Journal Article
Open access
CHChin Hu
Chin Hu
CLChun-Peng Liu
Chun-Peng Liu
JCJin-Shiung Cheng
Jin-Shiung Cheng
YCYu-Li Chiu
Yu-Li Chiu
HCHung-Pin Chan
Hung-Pin Chan
NPNan-Jing Peng
Nan-Jing Peng
Whole-body positron emission tomography/computed tomography with the glucose analog 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been extensively used to screen for underlying malignancies in asymptomatic individuals. We were able to survey a cohort of hospital employees using FDG-PET/CT and to report the results herein.A total of 116 hospital employees older than 55 years old were offered whole-body FDG-PET in our hospital. Ninety-seven employees (83.6%) completed the assessment from February 2014 to August 2014 in our PET center. The final confirmation of cancer was based on pathologic examination and follow-up after more than 1 year.Among the 97 participants, 92 were asymptomatic and 5 presented with previously diagnosed cancers. Six of the 92 asymptomatic participants (6.6%) with significant nodular lesions were referred for histological or cytological evaluation of the possibility of malignancy, and 1 case was considered clinically important and required surgical resection. The cancer discovery rate was 3.3% (3/92) with positive predictive value of 50% (3/6). In the 5 participants with previously identified cancers, no recurrence or metastasis was detected.The offer of whole-body FDG-PET for cancer screening was welcomed with enthusiasm by most of the hospital employees. PET/CT combines the merits of PET and CT and can be administered to and provide benefits to a select group of hospital employees.